DGX

Quest Diagnostics Inc. 10-Q Summary: Period Ended June 30, 2026

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Quest Diagnostics Inc. for the three and six months ended June 30, 2026. The Company operates primarily through its Diagnostic Information Services (DIS) segment, which accounts for over 95% of net revenues, providing laboratory testing and diagnostic insights. The remaining revenue comes from Diagnostic Solutions (DS), including risk assessment and healthcare IT. As of July 15, 2026, there were 110,373,360 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 10.2% year-over-year (Q2) and 9.7% (YTD), driven by organic growth of 10.0% and 9.5% respectively. DIS volume increased 13.1% (Q2) and 12.0% (YTD), significantly aided by new relationships with Corewell Health and Fresenius Medical Care.
• Profitability: Net income attributable to Quest Diagnostics rose 13.4% in Q2 and 13.9% YTD. Diluted EPS increased 15.0% (Q2) and 15.2% (YTD).
• Cost Structure: Cost of services increased 10.9% (Q2) and 10.0% (YTD), primarily due to higher compensation and supply costs from increased volume, partially offset by the "Invigorate" cost-saving program. SG&A increased 9.0% (Q2) and 7.5% (YTD).
• Debt Refinancing: In May 2026, the Company issued $500 million of 5.00% Senior Notes due 2036 and used proceeds to repay $500 million of 3.45% Senior Notes maturing in June 2026.
• Acquisitions: Completed a transaction with Corewell Health in January 2026 to form a new Michigan laboratory entity (51% owned by Quest), contributing to volume growth.

Guidance, Outlook, and Risks

• Invigorate Program: The Company continues a multi-year program targeting 3% annual cost savings and productivity improvements through automation and AI. $11 million in pre-tax restructuring charges were incurred YTD 2026.
• Capital Allocation: The Board authorized an additional $1 billion share repurchase in February 2026. $100 million was spent on repurchases YTD 2026, with $1.3 billion remaining available. Quarterly dividends were increased to $0.86 per share in 2026 (from $0.80 in 2025).
• Capital Expenditures: Estimated at approximately $550 million for 2026 to support laboratory automation and IT infrastructure (Project Nova).
• Risks and Contingencies:
  • Legal Proceedings: Ongoing investigations and litigation regarding the 2019 AMCA data security incident, Medicaid billing practices (NY and TX), and ERISA 401(k) plan claims. Reserves for legal matters totaled $17 million.
  • Professional Liability: Reserves for general and professional liability claims (including Irish pap smear screening allegations) totaled $174 million.
  • Market Risk: Exposure to interest rate changes is managed via $1.8 billion in notional interest rate swaps. A hypothetical 10% increase in rates would reduce debt fair value by approximately $152 million.

Investor Verification Checklist

• Organic Growth Sustainability: Verify if the 13% volume growth is sustainable without the specific Corewell and Fresenius contributions, which accounted for ~9% of the volume increase.
• Revenue Per Requisition: Monitor the 2.8% decline in revenue per requisition (Q2) driven by the mix of routine tests from new partners; confirm if pricing power remains intact in the core business.
• Debt Maturity Profile: Review the debt schedule; while the 2026 maturity was refinanced, significant maturities exist in 2029 ($1.1 billion) and 2030 ($801 million).
• Restructuring Execution: Track the realization of the 3% annual savings target from the "Invigorate" program against rising labor and benefit costs.
• Legal Reserve Adequacy: Assess the sufficiency of the $174 million professional liability reserve given the unpredictable nature of the Irish pap smear litigation and ongoing government investigations.